公开(公告)号：US20240358740A1

公开(公告)日：2024-10-31

申请号：US18766747

申请日：2024-07-09

申请人： William H. Cross, III

发明人： William H. Cross, III

IPC分类号： A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

CPC分类号： A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

摘要： The invention provides compositions and methods to treat diabetic neuropathies. In particular the invention has discovered that, in combination with a folic compound, particular combinations of two types of additional antioxidants have complementary effects for use against diabetic neuropathies. These include antioxidants that comprise stabilizing heteroatoms and antioxidants with an extended conjugated segment, where at least one of the antioxidants that comprises a stabilizing heteroatom also has pro-oxidant effects.

公开(公告)号：US20240350591A1

公开(公告)日：2024-10-24

申请号：US18299453

申请日：2023-04-12

申请人： Xygenyx Inc.

发明人： Alexy Goldstein

IPC分类号： A61K38/27 ,  A61K31/00 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7068 ,  A61K31/714

CPC分类号： A61K38/27 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/658 ,  A61K31/7068 ,  A61K31/714

摘要： A method and compositions of treatment using supplementation, comprising the step of applying a supplement formulation to a human subject via a selected administration route, the supplement formulation comprising therapeutically effective amounts of a hormone supplement, 5-MTHF, and P-5-P. The hormone supplement may comprise human growth hormone or a precursor or analogue thereof, and additional therapeutically-effective amounts of cannabinoids, citicholine, or methylcobalamin may be added.

公开(公告)号：US20240349771A1

公开(公告)日：2024-10-24

申请号：US18637077

申请日：2024-04-16

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： Nora Schneider ,  Jonas Hauser ,  Sean Deoni ,  Tamas Bartfai ,  Jonathan O'Regan

IPC分类号： A23L33/00 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A24B15/38 ,  A61K9/00 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28

CPC分类号： A23L33/40 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A24B15/38 ,  A61K9/0095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1564 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1618 ,  A23V2250/1642 ,  A23V2250/1846 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1862 ,  A23V2250/1886 ,  A23V2250/5424 ,  A23V2250/7056 ,  A23V2250/706

摘要： A synthetic nutritional composition containing a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

公开(公告)号：US12121042B2

公开(公告)日：2024-10-22

申请号：US18147860

申请日：2022-12-29

申请人： AJINOMOTO CO., INC.

发明人： Sachiko Yonemaru ,  Koji Haga ,  Yuki Miyazawa ,  Susumu Shibahara

IPC分类号： A23K20/142 ,  A23K20/158 ,  A23K20/174 ,  A23K40/25 ,  A23K40/35 ,  A23K50/10 ,  A61K31/198 ,  A61K31/405 ,  A61K31/455 ,  A61K31/519 ,  A61K31/714

CPC分类号： A23K20/142 ,  A23K20/158 ,  A23K20/174 ,  A23K40/35 ,  A23K50/10 ,  A61K31/198 ,  A61K31/405 ,  A61K31/455 ,  A61K31/519 ,  A61K31/714 ,  A23K40/25

摘要： Dispersion type feed additive compositions for ruminants, containing



(A) at least one selected from hydrogenated vegetable oil and hydrogenated animal oil each having a melting point of higher than 50° C. and lower than 90° C.,
(B) not less than 0.01 wt % and not more than 6 wt % of a surfactant,
(C) not less than 16 wt % and not more than 72 wt % of a biologically active substance (excluding L-lysine and a salt thereof), and
(D) not less than 1 wt % and not more than 40 wt % of L-lysine or a salt thereof,
contain a biologically active substance at a high concentration, show high protection in the rumen, and are also superior in dissolution in the intestinal tract.

公开(公告)号：US12115211B2

公开(公告)日：2024-10-15

申请号：US17945054

申请日：2022-09-14

申请人： Edgar Lee Hull, Jr.

发明人： Edgar Lee Hull, Jr.

IPC分类号： A61K38/44 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/30

CPC分类号： A61K38/443 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/30 ,  A61K38/446

摘要： A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

公开(公告)号：US20240325430A1

公开(公告)日：2024-10-03

申请号：US18743664

申请日：2024-06-14

申请人： JAYMAC PHARMACEUTICAL LLC

发明人： Rhett Sean Daniels ,  Harold Robinson

IPC分类号： A61K31/714 ,  A61K31/519 ,  A61K31/675 ,  A61K31/7008

CPC分类号： A61K31/714 ,  A61K31/519 ,  A61K31/675 ,  A61K31/7008

摘要： A multiple folate composition comprising the following three different forms of folate: a folic acid (a salt or ester thereof); a folinic acid (a salt or ester thereof); and a 5-methyl-tetrahydrofolicacid (a salt or ester thereof) and other non-folate ingredients. The composition is useful as a nutritional supplement or medication in the treatment of a folate deficiency and sequella thereof and/or in conditions responsive to administration of a metabolically useful folate. The compositions are particularly of use in patients who have impaired or reduced ability to convert folic acid to its metabolically active forms and in the treatment of depression, particularly in pregnant women or women who may become pregnant.

公开(公告)号：US20240299346A1

公开(公告)日：2024-09-12

申请号：US18596418

申请日：2024-03-05

申请人： Phi Health Sciences, Inc.

发明人： John-Paul Rowland ANDERSEN ,  Kirk Roy OUIMET

IPC分类号： A61K31/375 ,  A61K9/50 ,  A61K31/07 ,  A61K31/593 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K31/375 ,  A61K9/5084 ,  A61K31/07 ,  A61K31/593 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34

摘要： A dietary supplement bead may include a body comprising iron and vitamin C. A dietary supplement bead may include a microencapsulating material in the body, the microencapsulating material facilitating a sustained release of the iron and the vitamin C simultaneously within a small intestine of a user.

公开(公告)号：US20240238333A1

公开(公告)日：2024-07-18

申请号：US18392640

申请日：2023-12-21

申请人： Penland Foundation

发明人： Roland M. Williams

IPC分类号： A61K33/00 ,  A61K9/00 ,  A61K31/519 ,  A61K31/714 ,  A61P25/00

CPC分类号： A61K33/00 ,  A61K9/0043 ,  A61K31/519 ,  A61K31/714 ,  A61P25/00

摘要： Provided is a method of treating delirium in a patient in need thereof, the method comprising: administering nitrous oxide and oxygen to the patient and B-12 and/or folic acid, thereby treating delirium. A composition of the nitrous oxide and oxygen may comprise from about 1% nitrous oxide/about 99% oxygen to about 70% nitrous oxide/about 30% oxygen. The method may further comprise monitoring if the patient's neuroexcitatory substances level normalizes.

公开(公告)号：US20240226031A1

公开(公告)日：2024-07-11

申请号：US18094156

申请日：2023-01-06

申请人： Jonathan B. Andry

发明人： Jonathan B. Andry

IPC分类号： A61K31/05 ,  A61K31/197 ,  A61K31/198 ,  A61K31/405 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K36/185 ,  A61K36/82 ,  A61K36/9066 ,  A61K45/06

CPC分类号： A61K31/05 ,  A61K31/197 ,  A61K31/198 ,  A61K31/405 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K36/185 ,  A61K36/82 ,  A61K36/9066 ,  A61K45/06

摘要： A composition which provides a comprehensive solution for curbing, moderating and/or reducing the symptoms and cravings of opioid withdrawal syndrome. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. In accordance with embodiments of the invention a composition for treating opioid withdrawal syndrome is provided. The composition includes (i) a therapeutically effective amount of a functional blend comprising a mixture of cannabidiol, cannabigerol, gamma aminobutyric acid, Inositol, and Vitamin B-12; (ii) a therapeutically effective amount of a hydration blend comprising a mixture of calcium, magnesium, potassium citrate, and L-glutamine; (iii) a therapeutically effective amount of an anti-inflammatory blend comprising a mixture of turmeric, green tea, and passion fruit; and (iv) a therapeutically effective amount of a neurotransmitter blend comprising 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and/or ameliorates the deleterious symptoms of opioid cessation and withdrawal. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and/or ameliorates the potentially incessant drug cravings and the associated anxiety and stress.

公开(公告)号：US12029750B2

公开(公告)日：2024-07-09

申请号：US17805479

申请日：2022-06-06

申请人： William H. Cross, III

发明人： William H. Cross, III

IPC分类号： A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

CPC分类号： A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

摘要： The invention provides compositions and methods to treat diabetic neuropathies. In particular the invention has discovered that, in combination with a folic compound, particular combinations of two types of additional antioxidants have complementary effects for use against diabetic neuropathies. These include antioxidants that comprise stabilizing heteroatoms and antioxidants with an extended conjugated segment, where at least one of the antioxidants that comprises a stabilizing heteroatom also has pro-oxidant effects.